17 results about "Chemotherapy regimen" patented technology

The application belongs to the technical field of medical information, and discloses a tumor chemotherapy scheme individualized adjustment and curative effect evaluation method and system. Static basic data, dynamic treatment data, single cell sequencing data and structured data of doctor-patient conversation are comprehensively collected in the data fusion quality control stage. Format adaptation and semantic alignment of cross-modal data are realized through a unified standardized interface. Data quality control is carried out in combination with an isolated forest algorithm, and only high-quality data with a score of 80 or more are included to provide a reliable basis for scheme development. In the multi-module collaborative prediction stage, a medical knowledge graph and a hybrid modeling framework are fused, multi-center data is jointly trained, and drug sensitivity scores are accurately output. When the scheme is generated, the clinical guidelines and patient needs are linked, multi-constraint rule reasoning and multi-objective optimization are used to develop individualized schemes that adapt to the patient's genetic characteristics, pathological types and quality of life demands, and reduce the risk of poor efficacy and serious adverse reactions caused by individual differences.

The present invention relates to a combination therapy regimen of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen, and to the use of this therapy regimen as a means of treating cancer in patients who require cancer treatment, particularly in patients with fibrous cancers / tumors such as pancreatic cancer. Accordingly, the first embodiment provides a method for treating cancer in a subject who requires cancer treatment, comprising administering a combination of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

The invention discloses an adverse reaction dynamic monitoring and follow-up management system after chemotherapy, and relates to the technical field of data processing, and the system comprises an acquisition module which determines a to-be-monitored symptom and a corresponding target part according to a chemotherapy regimen of a patient, and receives an image of the target part; the recognition module carries out registration on the part partition map and the target part image, a reaction partition with an abnormal color block area is determined, and color block positioning points are marked; the analysis module generates a positioning acquisition frame according to the part partition to which the color block positioning points belong, receives the review part image, cuts the target part image and the review part image based on the positioning acquisition frame, and determines the point location diffusion amount; and the decision-making module determines a follow-up visit mode according to the point location diffusion amount and the partition position of the reaction partition. The patient is guided to review and shoot the same position through the positioning collection frame, the follow-up visit mode is determined in combination with the partition positions, and the accuracy of follow-up visit decision is improved.

The invention discloses an AML chemotherapy regimen sharing method and system based on distributed processing, and belongs to the technical field of medical information. The method comprises the following steps: acquiring clinical data related to an AML chemotherapy regimen, including patient information, pathological indexes and iconography data, performing preprocessing and semantic annotation, and generating a semantic clinical data unit with a distributed identifier; registering the identifier, the metadata and the digital signature to a distributed account book network maintained by multiple mechanisms; receiving a query request based on the semantic tag and the metadata, and matching a data unit in an account book network through a semantic engine; and after verifying the authority of the requester, transmitting a data load or executing a distributed computing task of which the data cannot be out of the domain through the secure channel. The problems of privacy security, cross-mechanism interoperation and credible authentication in clinical data sharing are effectively solved, and an efficient and reliable data collaboration platform is provided for AML diagnosis and treatment research.

The invention discloses a method for improving chemotherapy efficiency of a tumor department. The method comprises the following steps that a whole disease course management system is utilized, after a chemotherapy regimen of a patient is determined, individual case management and the patient confirm follow-up return time, within effective time before the return time, the system will inform a user to complete specified biochemical inspection, the patient uploads an effective inspection list to the system, and the system automatically judges whether the condition of next chemotherapy is met or not; submitting examinations and medical records of the patients meeting the conditions to doctors of the daytime chemotherapy center, and making prescriptions by the doctors according to results; the system informs the patient of exact hospital return date and time and appointment a bed, the patient directly checks in the daytime chemotherapy center according to appointment prompts in the system after arriving at the hospital, the daytime chemotherapy center confirms that elements are complete, medicines are directly dispensed, infusion is arranged, and the patient can directly leave the hospital after infusion is finished. The method has the beneficial effects that the preparation time of a patient before chemotherapy is shortened; the extra expenditure of outpatient service is reduced; the bed utilization efficiency is improved.

The invention belongs to the technical field of application of traditional Chinese medicine preparations, and discloses application of Jinshuiliujun decoction in preparation of a medicine for treating EGFR sensitive mutation non-small cell lung cancer, the medicine is used for being applied in combination with chemotherapy, a classic traditional Chinese medicine compound is combined with a modern chemotherapy regimen, and when a patient suffering from IIIb / IV-stage EGFR sensitive mutation is treated, the curative effect is good, and the curative effect is good. The pharmaceutical composition shows clear synergistic interaction and toxicity reduction effects, and the specific performance is as follows: the median progression-free lifetime of a patient is obviously prolonged; the traditional Chinese medicine syndromes such as cough and weakness are improved; the immunologic function is effectively regulated, and the CD4 + / CD8 + ratio is increased; the negative emotion score of the patient is reduced; the adverse reaction incidence rate of chemotherapy is not increased; a brand new traditional Chinese and western medicine combined treatment scheme is provided for the specific lung cancer subtype, and the curative effect and life quality are improved.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

This invention provides an immunomodulator for use in the treatment, reduction, inhibition or control of cancer subject, wherein the subject is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the ECOG Scale, or classified as not being of an age and / or not being sufficiently fit to tolerate two or more chemotherapy regimens. The invention also describes the use of one or more additional anticancer treatments or agents as well as protocols and dosage regimens for use.

The invention provides an AML chemotherapy regimen bone marrow morphology prediction method and device based on bone marrow next-generation sequencing. The method comprises the following steps: acquiring bone marrow next-generation sequencing data of an AML patient before treatment, extracting an associated mutant gene list from the bone marrow next-generation sequencing data, then mapping the associated mutant gene list to an AML field knowledge graph, acquiring each target node successfully mapped by the associated mutant gene list in the AML field knowledge graph, and determining the target node according to the acquired target node. Feature settlement corresponding to each target node is extracted from the AML domain knowledge graph, the feature settlement is a connected sub-graph which takes the target node as the center and is determined according to a predefined topology rule, the feature settlement corresponding to each target node is input into a bone marrow morphology prediction model, and a bone marrow morphology prediction model is obtained. The method solves the problem that in the prior art, the bone marrow morphology cannot be predicted before chemotherapy, so that an original refractory patient cannot be recognized in a prospective manner.

The invention belongs to the technical field of antitumor drugs, and particularly relates to a CXCR2 modified CD276-CAR-NK cell and a chemotherapeutic drug which are combined for treating esophageal cancer. The invention firstly provides application of the natural killer cell combined chemotherapy medicine in preparation of anti-tumor products. The natural killer cell is a CAR-NK92 cell or a CD276-CAR-NK92 cell which is modified by CXCR2 and takes CD276 as a target spot. The invention also provides an application of the natural killer cell combined chemotherapy drug in preparation of drugs for inhibiting proliferation of esophageal cancer cells or promoting apoptosis of the esophageal cancer cells. According to the invention, the natural killer cell which plays an important role in an anti-tumor surface is combined with a chemotherapeutic drug for application. Experimental results show that esophageal cancer cells or esophageal squamous cell carcinoma cells can be effectively killed in vitro, and proliferation of tumor cells can be remarkably inhibited in an in-vivo experiment. According to the invention, beneficial exploration is carried out for seeking an updated, safe and effective chemotherapy regimen, and a technical basis is provided for research of combined application of chemotherapy and other cell therapy and preparation of antitumor drugs.

The present application relates to a kind of recombinant complement protein and the application in the preparation of anti-leukemia drugs, belong to biological medicine technical field;The present application discloses that single drug treatment, i.e. injection recombinant C1QBP protein has significant effect in the treatment of acute leukemia, can significantly inhibit the proliferation of leukemia cells in hematopoietic system bone marrow, spleen, peripheral blood, while inhibiting the infiltration of leukemia cells in extramedullary organs (skin, etc.), thereby reducing the whole body tumor load, significantly prolonging the survival period of leukemia mouse.Recombinant C1QBP protein is combined with clinical first-line chemotherapy regimen, has synergistic effect, compared with single use chemotherapy drug has stronger effect of inhibiting the proliferation of leukemia cells, can significantly prolong the survival period of leukemia mouse, has played the effect of attenuated and synergistic effect.The present application first proves that complement C1Q binding protein has the effect of treating leukemia, and provides preparation method and combined drug regimen, has higher clinical conversion prospect and application value.

The application discloses a processing method and device of hypopharyngeal carcinoma induction chemotherapy prognosis prediction and treatment scheme and a medium, which can be applied to the technical field of big data processing. The application obtains a plurality of historical multi-modal information of a plurality of historical primary treatment hypopharyngeal carcinoma patients before induction chemotherapy, including a first CT image, first clinical text information, a first induction chemotherapy scheme selected by the historical primary treatment hypopharyngeal carcinoma patient and total survival time. Then, the preset model is trained through the historical multi-modal information, and then the score cutoff value corresponding to the training completion of the preset model is determined. Then, the current multi-modal information of the current primary treatment hypopharyngeal carcinoma patient before induction chemotherapy is input into the trained preset model to predict a current risk value. Then, the target recommended scheme of induction chemotherapy is determined based on the current risk value and the score cutoff value, so that the determined target recommended scheme is closer to the actual situation, and the matching degree of the recommended chemotherapy scheme and the actual situation is improved.

The invention discloses application of salidroside in preparation of a medicine for enhancing sensitivity of lung cancer combined diabetes chemotherapy. The application firstly researches and verifies that the salidroside can enhance the sensitivity of lung cancer combined with diabetes to chemotherapeutic drugs, and particularly, the salidroside can obviously enhance the sensitivity of lung cancer combined with diabetes to paclitaxel, so that the anti-tumor treatment effect is improved; a new treatment strategy is provided for optimization of a chemotherapy regimen of a patient with lung cancer combined with diabetes in clinic, a new candidate active component is also provided for preparation of an adjuvant therapy drug for enhancing chemotherapy sensitivity, and the application has important value and significance in improvement of treatment prognosis of the patient with lung cancer combined with diabetes.

The invention discloses an ovarian cancer chemotherapy regimen recommendation method based on drug sensitivity prediction, and relates to the field of data analysis. The method comprises the steps that a drug sensitivity general recognition model cluster is established according to historical scheme records of ovarian cancer chemotherapy, and the drug sensitivity general recognition model cluster comprises a metabolic kinetics meta-model, a side effect intensity meta-model and a recovery degree-side effect violation meta-model which are cascaded; static feature information and historical chemotherapy records of a target patient are obtained, the drug sensitivity general recognition model cluster is subjected to rapid adaptation, and a sensitivity specialized model cluster of the target patient is obtained; and based on the sensitivity specialized model cluster, performing optimization decision on a chemotherapy regimen, and outputting a recommended chemotherapy regimen. According to the invention, pertinence and accuracy of ovarian cancer chemotherapy regimen recommendation are effectively improved.